3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Neoplasms
2
Hemorrhage
2
Thrombocytopenia
1
Recurrence
1
Postoperative Hemorrhage
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Blood Loss, Surgical
1
Interventions
Specimen Handling
9
fludarabine
8
Cyclophosphamide
7
Biopsy
6
ruxolitinib
5
Whole-Body Irradiation
5
Stem Cell Transplantation
5
Azacitidine
5
venetoclax
4
Tacrolimus
4
Injections
4
Cytarabine
4
Busulfan
4
ivosidenib
3
fludarabine phosphate
3
Thiotepa
3
Mycophenolic Acid
3
Melphalan
3
Cyclosporins
3
CPX-351
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
luspatercept
2
decitabine and cedazuridine drug combination
2
X-Rays
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Liposomes
2
Gemtuzumab
2
Daunorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Myeloproliferative Disorders
×
Tranexamic Acid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled